Le Lézard
Classified in: Health
Subject: FDA

Novadoz Pharmaceuticals/MSN Labs Receives FDA Clearance for Fosaprepitant and Decitabine the Company's First Generic Specialty Injectable Products


PISCATAWAY, N.J., Sept. 5, 2019 /PRNewswire/ -- Novadoz Pharmaceuticals, the U.S based sales & marketing affiliate for MSN Labs, based in Hyderabad India, has received FDA approvals for their generic versions of Decitabine and Fosaprepitant for injection.  Decitabine was approved on August 29th, and Fosaprepitant gained clearance today.  The company has immediately commenced shipping of Fosaprepitant, which coincides with the first day of patent expiration for the brand EMEND©, marketed by Merck.  Novadoz expects to begin the shipping of Decitabine, their generic version of DACOGEN© from Otsuka, later this month.     

(PRNewsfoto/Novadoz Pharmaceuticals)

The combined sales of Decitabine brand and generics is trending over $91MIL, while brand sales of Fosaprepitant are approximately $279MIL during the previous twelve months of published sales.  Decitabine is available as 50mg single-dose vial used to treat a group of blood/bone marrow disorders in cases when bone marrow does not produce enough healthy blood cells. Fosaprepitant is a is a sterile, lyophilized formulation available as a single vial, and indicated  to prevent acute and delayed nausea and vomiting associated with initial and repeat courses of chemotherapy. 

Seshu Akula, Novadoz President North America Generics, states "The approval of Fosaprepitant and Decitabine for injection, mark the company's entrance into the specialty injectable market.  The introduction of Fosaprepitant, as well as our earlier approvals for Abiraterone, and Capecitabine, further the organization's commitment to be a leading supplier of oncology products. We expect several additional approvals over the next year adding to our growing line of specialty products."

MSN Labs is engaged in the development and manufacturing of API (active pharmaceutical ingredients), KSMs (key starting materials), and product intermediates.  MSN is a global leader in this category.  In addition, the company manufactures finished dosage oral solids, liquids, and injectable products in sixty-five markets throughout the world, doing business in the U.S under the Novadoz label.

For more information, visit the company's websites at NovadozPharma.comMSNLabs.com

CONTACT:
Tom DeStefano
Novadoz Pharmaceuticals
Vice President Sales and Marketing
(848) 200-1909

SOURCE Novadoz Pharmaceuticals


These press releases may also interest you

at 03:00
Sadly, senior citizens are among the first to suffer from exposure to COVID-19. Living in close quarters is one of the highest contributing factors to exposure but the team from San Luis Obispo's Elder Placement Professionals has prepared some...

4 jui 2020
SummaryProducts: Cetrotide 0.25mg Issue: One lot of Cetrotide 0.25mg is being recalled because some vials may have missing stoppers, which could make the product unsterile. What to do: Check the lot number on your product or contact your pharmacist...

4 jui 2020
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "There have been 105,091 cases of COVID-19 in Canada, including 8,663 deaths. 65% of people have now recovered....

4 jui 2020
The latest data of the evolution of COVID-19 in Québec reveal 102 new cases over the past 24 hours, bringing the total number of people infected to 55,784. During the same period, 3 new deaths were recorded, to which are added 3 deaths that occurred...

4 jui 2020
On Friday, the British government announced that, as of July 10th, those travelling from the Commonwealth of Dominica to England need not self-isolate for 14 days. Dominica is one of the 59 countries and 14 British Overseas Territories forming a...

4 jui 2020
Gilead Sciences, Inc. today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the company's investigational, novel inhibitor of HIV-1 capsid function, lenacapavir (GS-6207), sustained...



News published on 5 september 2019 at 16:59 and distributed by: